ORIC Pharmaceuticals (ORIC) Analyst & Key Data

Analyst Consensus

Buy7 analysts

Buy

Updated Sep 12, 2026

Total Analysts7

Buy

10

Ratings

Updated Sep 12, 2026

Overall Rating

C+

DCF Score3.0 / 5

Debt / Equity Score4.0 / 5

Price / Book Score2.0 / 5

Price / Earnings Score1.0 / 5

ROA Score1.0 / 5

ROE Score1.0 / 5

Valuation

Current Stock Price

$12.04

Median Target+80.32%

$21.71

Potential upside vs current price

DCF Value-97.10%

$0.35

Potential downside vs current price

Current Stock Price

$12.04

Median Target+80.32%

$21.71

Potential upside vs current price

DCF Value-97.10%

$0.35

Potential downside vs current price

Analyst Consensus

Buy7 analysts

Buy

Updated Sep 12, 2026

Total Analysts7

Buy

10

Ratings

Updated Sep 12, 2026

Overall Rating

C+

DCF Score3.0 / 5

Debt / Equity Score4.0 / 5

Price / Book Score2.0 / 5

Price / Earnings Score1.0 / 5

ROA Score1.0 / 5

ROE Score1.0 / 5

Valuation

Current Stock Price

$12.04

Median Target+80.32%

$21.71

Potential upside vs current price

DCF Value-97.10%

$0.35

Potential downside vs current price

Current Stock Price

$12.04

Median Target+80.32%

$21.71

Potential upside vs current price

DCF Value-97.10%

$0.35

Potential downside vs current price

ORIC Pharmaceuticals, Inc.